The Cervin Group aims to improve outcomes for patients who suffer from debilitating chronic sinus and ear infections. A primary focus of the lab is to gather new knowledge on the microbiome of the sinus, ear, nose and throat during health and to understand how the biome differs in patients with chronic sinus and ear infections. The Cervin Group is also working to develop microbiome therapies that will reduce problematic infections in the sinus and ears.

  • Honorary Professor Anders Cervin

    Garnett Passe and Rodney Williams Foundation Chair in Otolaryngology at the University of Queensland
    Honorary Professor
    UQ Centre for Clinical Research
  • Dr Diane Maresco-Pennisi

    Postdoctoral Research Fellow/Research Officer
    UQ Centre for Clinical Research
    Postdoctoral Research Fellow
    Faculty of Medicine


  • Dr Seweryn Bialasiewicz, University of Queensland
  • The Deadly Ears Program, Queensland Health
  • The Garnett Passe and Rodney Williams Memorial Foundation, Australia
  • Professor Flavia Huygens, Queensland University of Technology
  • Royal Brisbane and Women’s Hospital
  • ENT Technologies


  • Dr Eva Grahn Hakansson
  • Dr Anders Maretnsson
  • Dr Charlotte Simark Mattson
  • Dr Kristian Roos
  • Lund University, Sweden
  • Winclove Probiotics
  • An exploratory safety study of 480 biomedical mometasone furoate sinus drug depot (MFSDD) in adult patients with chronic sinusitis.
  • A randomized, double­blind, 52­week, placebo controlled efficacy and safety study of dupilumab, in patients with bilateral nasal polyposis on a background therapy with intranasal corticosteroids.
  • The Nasal Microbiota Transfer
Doomadgee in Queensland’s Gulf Country, and Mareeba on the Atherton Tablelands, are worlds away from the Herston research laboratory of Professor Anders Cervin.